TP53 and myeloproliferative neoplasm: TP53 mutations were detected in three (14%) cases, and the mutations were either with low VAFs (<2%) and transient (in an MDS case and an MDS/MPN case) or persistent at low levels (VAF<3%, in an MDS case), suggesting that TP53 may not be a key player in these cases.